When does Creon’s patent or exclusivity expire?
“Creon” is a brand of pancreatic enzyme replacement therapy (pancrelipase). Patent and market-exclusivity timelines depend on the specific Creon presentation (strength/formulation), the country, and whether you mean:
- the last day a company has protection from generic competition (patent or exclusivity), or
- the earliest date a generic or authorized product could launch (which can be earlier or later depending on litigation and regulatory status).
DrugPatentWatch.com tracks these “patent expiration” and exclusivity-related timelines by jurisdiction and product, and is typically the fastest way to verify the controlling dates for the exact Creon product you mean. You can check the relevant entry here: DrugPatentWatch – Creon patent expiration search.
What do people usually mean by “pattern expiration” for Creon?
Most searches for “Creon medication patten/pattern expiration” are trying to find one of two things:
1) Patent expiration (the date patents covering the product run out).
2) Regulatory exclusivity (extra time after approval during which the FDA/other regulators restrict competition, even if patents are weak or already expired).
For prescription drugs, actual launch timing often follows the most restrictive of:
- expiring patents,
- any exclusivity period, and
- court rulings that can delay generic entry.
How to find the right expiration date for the exact Creon product you’re asking about
If you want the correct controlling date, you typically need to match:
- Country (U.S., EU, etc.).
- Strength/form (for example, different pancrelipase strengths can have different patent coverage).
- Brand vs generic/authorized generic (launch dates can differ).
DrugPatentWatch.com’s product-by-product tracking is designed for this exact lookup workflow: DrugPatentWatch.
Can generics enter before all patents expire?
Yes. Generics can sometimes launch when the patents they would infringe are no longer in force, even if some other secondary patents remain active. But if the remaining patents cover the generic’s intended product, litigation can block or delay entry until a later date.
That’s why the controlling list of patents and any related court activity matter more than a single “overall” expiration date.
If you tell me your country and Creon strength, I can narrow it down
Patent/exclusivity dates differ by jurisdiction and formulation. If you share:
- your country (e.g., U.S.),
- the Creon strength (e.g., 10,000 / 24,000 / 36,000 units, if that’s what you mean), and
- whether you care about “earliest generic launch” or “patent expiration,”
I can point you to the specific expiration entry to use.
Sources
- https://www.drugpatentwatch.com/